Investigational Allo-HSCT for Advanced Hematologic Malignancies

EP: 1.Role of Allogeneic Transplants in Hematologic Malignancies

EP: 2.Hematologic Malignancies and Transplant Options and Conditioning Regimens Used in Allo-HSCT

EP: 3.Supportive Care Measures for Patients Planning to Receive an Allogenic Transplant

EP: 4.Transplant Complications and Survival Outcomes

EP: 5.Clinical Trial Update: CTN Trial

EP: 6.Graft-versus-Host Disease Prophylaxis and Management

EP: 7.Patient Case Studies of GvHD

EP: 8.Emerging Cellular Therapies in Hematologic Malignancies

EP: 9.Transplant in the Elderly Population

EP: 10.Toxicity Assessment of Precision-Engineered Allo-HSCT

EP: 11.The Role of Allo-HSCT in Higher-Risk MDS

Now Viewing

EP: 12.Investigational Allo-HSCT for Advanced Hematologic Malignancies

EP: 13.The Future of Allo-HSCT and Cellular Therapies

EP: 14.OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion

This is a video synopsis/summary of a Peer Exchange featuring Miguel-Angel Perales, MD; Nelli Bejanyan, MD; Amandeep Salhotra, MD; and Arpita Gandhi, MD, MS.

The panel discusses the Orca-Q product, a cellular therapy developed by Orca Bio for nonmalignant disorders, which differs from the Orca-T graft used in malignant settings. The Orca-Q product utilizes naive T-cell depletion from the peripheral blood stem cell graft while retaining the memory T-cell population, which confers graft-vs-leukemia (GVL) effects and prevents infectious complications.

The phase 1 dose escalation study has been completed, reaching the target memory T-cell dose level of 100 million cells/kg, and will be expanded.

The Orca-Q product is being tested in both matched donor and haploidentical transplant settings. Data on 33 patients who underwent haploidentical transplantation after myeloablative conditioning was presented at the 2023 American Society of Hematology Annual Meeting & Expo. The Orca-Q graft allows for haploidentical transplantation without the use of post-transplantation cyclophosphamide, potentially reducing complications such as hemorrhagic cystitis, cytopenias, and high-dose chemotherapy-related issues. The study reported low rates of chronic graft-vs-host disease (GVHD; no GVHD at 1-year follow-up), acute GVHD (less than 5%), and cytokine release syndrome. The panel expects the study to be expanded, providing results in both matched donor and haploidentical settings.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.